Polytrim Ophthalmic Dosing
For mild to moderate bacterial conjunctivitis, instill one drop of Polytrim (polymyxin B 0.5%/trimethoprim 0.1%) ophthalmic solution in the affected eye(s) every 3 hours (maximum 6 doses per day) for 7 to 10 days. 1, 2
Standard Dosing Regimen
- Adults: 1 drop every 3 hours while awake, not exceeding 6 doses daily, for 7-10 days 1, 2
- Pediatric patients >2 months: Same dosing as adults—1 drop every 3 hours (maximum 6 doses/day) for 7-10 days 1
Key Clinical Considerations
Efficacy Profile
- Polytrim demonstrates clinical cure rates of 72-96% for bacterial conjunctivitis by day 7-10 of treatment 3
- The medication shows equivalent efficacy to newer fluoroquinolones like moxifloxacin, with 96% clinical cure rates in head-to-head trials 3
- However, moxifloxacin achieves faster symptom resolution (81% complete resolution at 48 hours vs 44% with Polytrim), though both achieve similar final cure rates 4
Spectrum and Resistance
- Polytrim maintains 100% susceptibility against Pseudomonas aeruginosa ocular isolates (average MIC 0.416 ± 0.135 µg/mL) 5
- The combination is effective against common conjunctivitis pathogens including Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis 3
- Resistance rates remain negligible (0%) for the polymyxin B/trimethoprim combination 5
Common Pitfalls to Avoid
- Do not confuse with Polytrim ointment formulations: The evidence provided references a different product (neomycin/polymyxin B/dexamethasone ointment) with different dosing (3-4 times daily) 6—this is NOT the same as Polytrim solution
- Ensure adequate dosing frequency: The every-3-hours regimen (6 times daily) is more frequent than many newer antibiotics but is necessary for optimal efficacy 1, 2
- Complete the full course: Despite symptom improvement, bacterial eradication requires the full 7-10 day treatment duration 1, 3
Cost-Effectiveness Consideration
Polytrim represents a significantly more cost-effective option compared to fluoroquinolones while maintaining equivalent clinical cure rates, making it an appropriate first-line choice for uncomplicated bacterial conjunctivitis 3